Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.
What Is a Regulatory T Cell?
Regulatory T cells (Tregs) are a CD4+ T cell subset defined by expression of the transcription factor FoxP3, high surface CD25 (IL-2 receptor alpha), and low or absent CD127 (IL-7 receptor alpha). They suppress effector T cell proliferation and cytokine production through contact-dependent mechanisms (CTLA-4, PD-L1) and soluble factors (IL-10, TGF-β, IL-35). In healthy donors, Tregs represent approximately 5–10% of circulating CD4+ T cells and maintain peripheral immune tolerance.
In autoimmune disease, this system breaks down. The mechanisms vary by indication, but the downstream result is consistent: Tregs from donors with active autoimmune disease are functionally distinct from healthy donor Tregs, and research that uses healthy donor Tregs as a proxy for patient biology will miss clinically relevant failure modes.
Why Disease-State Tregs Differ From Healthy Donor Controls
The dysfunction is not uniform across conditions. Understanding the indication-specific failure mode is prerequisite to designing a suppression assay that actually measures what your therapy needs to do.
| Indication | Treg dysfunction phenotype | Research implication |
|---|---|---|
| SLE | FoxP3 instability; Treg→Th17 conversion under IL-6 | Suppression assays must include inflammatory cytokine conditions |
| Rheumatoid Arthritis | Normal frequencies, impaired suppressive function | Titration curves will plateau lower than healthy donor controls |
| Multiple Sclerosis | Reduced frequency in active relapse; impaired IL-10 secretion | Relapsing vs. remitting donors show different phenotypes |
| Type 1 Diabetes | Preserved FoxP3, reduced IL-10 and TGF-β secretion | Cytokine-based readouts will diverge from healthy controls |
| Psoriasis / PsA | Th17-skewed environment destabilizes FoxP3 co-expression | RORγt co-expression should be assessed alongside FoxP3 |
| Sjögren’s Syndrome | Reduced glandular Treg infiltration; normal periphery frequency | Peripheral blood Tregs may not reflect glandular immune environment |
Starting Material: What Disease-State PBMCs Provide
Treg isolation requires high-viability starting material. CD25hi cells are among the more fragile CD4+ subsets — viability below 80% post-thaw significantly reduces CD25hi recovery and increases background in functional assays from dead-cell artifact.
OrganaBio disease-state PBMCs are cryopreserved at a target viability ≥85%, with documented cell counts, viability at freeze, and lot-release testing. Donors carry confirmed diagnosis documentation, disease-relevant serology (ANA, anti-dsDNA, RF, anti-CCP as applicable), medication history, and HLA typing. For HLA-restricted Treg research — particularly in RA (DRB1 shared epitope) and T1D (DQ2/DQ8/DR4) — HLA data enables donor selection matched to patient populations in clinical trials.
Fresh leukopaks are available for same-day processing protocols where cryopreservation effects on CD25 expression are a concern. OrganaBio processes collections within 30 minutes of receipt, preserving cell surface marker integrity that degrades with extended transit time.
Treg Isolation Protocol From Disease-State PBMCs
This protocol describes CD4+CD25+CD127lo/− enrichment by magnetic separation, the standard approach for isolating viable Tregs for functional assays. Starting cell count recommendations assume cryopreserved PBMC input at ≥85% viability.
Step 1: PBMC Thaw and Rest
Thaw cryopreserved PBMCs in a 37°C water bath using a rapid-thaw protocol (<2 minutes in bath). Transfer dropwise into pre-warmed complete medium (RPMI 1640 + 10% heat-inactivated human AB serum + pen/strep). Centrifuge at 300 × g for 10 minutes, discard supernatant, resuspend in complete medium. Allow cells to rest at 37°C / 5% CO₂ for 1–2 hours before proceeding. Resting reduces cryopreservation-induced activation artifacts on CD25 surface expression.
Count and viability check: Target ≥80% viability post-thaw. If viability is <80%, consider dead-cell removal before proceeding (see Step 2). Input requirement: 50–100 million total PBMCs to recover sufficient Tregs for a suppression assay (typical Treg yield: 500K–2M cells depending on donor and indication).
Step 2: Dead Cell Removal (Optional but Recommended)
Dead cells non-specifically bind antibodies and increase background. For disease-state donors, where viability can be variable, dead-cell depletion before Treg isolation improves purity. Use a magnetic dead-cell removal kit (e.g., Miltenyi Dead Cell Removal Kit) per manufacturer’s protocol. Post-removal viability target: ≥90%.
Step 3: CD4+ Pre-Enrichment
Deplete non-CD4+ cells using a CD4+ negative selection kit (untouched CD4+ enrichment). This reduces starting cell number before the CD25 selection step, which improves CD25hi capture efficiency and reduces reagent consumption. Typical CD4+ yield from disease-state PBMCs: 25–40% of total PBMCs, varying by indication (SLE donors may have altered CD4:CD8 ratios).
Step 4: CD25hi Positive Selection
Apply CD25 MicroBeads (or equivalent) to the CD4+ pre-enriched fraction per manufacturer protocol. Use the recommended column and magnet configuration for your cell number. Elute the CD25hi fraction. At this stage, the CD25hi fraction contains both Tregs (CD25hiCD127lo/−FoxP3+) and activated effector T cells (CD25+CD127+FoxP3−). Step 5 resolves this.
Yield note: CD25hi cells represent ~1–3% of total PBMCs in healthy donors. Disease-state donors may yield lower CD25hi fractions (MS, T1D) or comparable frequencies with impaired function (RA). Plan cell input accordingly.
Step 5: CD127lo/− Depletion
Label the CD25hi fraction with anti-CD127 and deplete CD127+ cells by magnetic separation. This step removes activated non-Treg cells that co-express CD25. The resulting CD4+CD25+CD127lo/− population is ≥85–90% pure FoxP3+ by intracellular staining in most donors. For disease-state donors with high background activation (active SLE, active RA), purity may be lower — validate by flow on each lot.
Step 6: FoxP3 Validation by Intracellular Staining
Aliquot a fraction of the CD4+CD25+CD127lo/− fraction for intracellular FoxP3 staining (fixation/permeabilization required). Use a validated FoxP3 clone (clone 236A/E7 or PCH101). Accept the isolation if FoxP3+ percentage ≥80% of the CD4+CD25+CD127lo/− gate. For SLE donors, additionally assess RORγt co-expression to identify ex-Treg / Th17-convertible subpopulations.
Suppression Assay Design
The suppression assay measures Treg-mediated inhibition of effector T cell proliferation. For disease-state research, effector cells should come from the same indication donor where possible — healthy donor effectors suppress differently than autoreactive effectors from the target indication.
Effector T Cell Preparation
Isolate CD4+CD25− T cells (Teff) from either the same donor or an indication-matched control. Label with a proliferation dye (CFSE or CellTrace Violet). Stimulate with anti-CD3/CD28 beads or plate-bound anti-CD3 at a concentration that produces 80–90% proliferation in the absence of Tregs (typically 0.5–1 μg/mL anti-CD3 for 72–96 hours).
Treg:Teff Ratio Titration
Set up ratios across at least 4 points: 1:1, 1:2, 1:4, 1:8 (Treg:Teff). Plate at 1×10⁵ Teff per well minimum. Include: (1) Teff alone with stimulation (maximum proliferation control), (2) Teff without stimulation (baseline proliferation control), (3) Treg alone with stimulation (Treg proliferation control). Read at 96 hours by flow cytometry (% undivided cells in CFSE/CTV gate). Calculate percent suppression: (% proliferating in absence of Treg − % proliferating with Treg) / % proliferating in absence of Treg × 100.
Disease-state interpretation note: RA-derived Tregs typically show a rightward shift in the suppression curve compared to healthy donor Tregs at equivalent ratios. Do not interpret this as an assay failure — it reflects the biologically relevant impairment. Run a healthy donor control alongside every disease-state experiment to establish the delta.
Cytokine Readout Option
For Tregs from T1D donors, where IL-10 secretion is reduced despite FoxP3+ expression, add an IL-10 and TGF-β multiplex panel to the assay supernatant. Proliferation suppression and cytokine secretion can dissociate in T1D Tregs — a compound readout captures both mechanisms.
Ordering Disease-State Tregs From OrganaBio
OrganaBio disease-state PBMCs for Treg research are available cryopreserved or as fresh leukopaks, with donor documentation covering diagnosis, disease-relevant serology, medication history, HLA type, and lot-release viability. Indication coverage includes SLE, RA, MS, T1D, psoriasis, psoriatic arthritis, Sjögren’s, and 17 additional autoimmune conditions.
For programs requiring matched healthy donor controls from the same collection period, OrganaBio can provide side-by-side lots. Contact the scientific team to discuss donor selection criteria, HLA requirements, and fresh versus cryopreserved format for your assay system.
